Highlights ANI Pharmaceuticals, Inc.

Equities

ANIP

US00182C1036

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
65.5 ^USD	+0.21%		-0.18%	+18.79%

Apr. 17	Ani Pharmaceuticals Insider Sold Shares Worth $1,500,589, According to a Recent SEC Filing	MT
Apr. 09	ANI Pharmaceuticals, Inc. Announces the Launch of Baclofen Oral Suspension	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ANI Pharmaceuticals, Inc. Announces the Launch of Baclofen Oral Suspension	Apr. 09	CI
ANI Pharmaceuticals, Inc. Announces the Launch of Levofloxacin Oral Solution, USP	Mar. 27	CI
ANI Pharmaceuticals Shares Rise After Q4 Adjusted Earnings, Net Revenue Beat Forecasts	Feb. 29	MT
ANI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
ANI Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024	Feb. 29	CI
(ANIP) ANI PHARMACEUTICALS Sees Fiscal Year 2024 Revenue Range $520M - $542M	Feb. 29	MT
(ANIP) ANI PHARMACEUTICALS Expects Fiscal Year 2024 EPS Range $4.26 - $4.67	Feb. 29	MT
Earnings Flash (ANIP) ANI PHARMACEUTICALS Posts Q4 Revenue $131.7M, vs. Street Est of $124.9M	Feb. 29	MT
Earnings Flash (ANIP) ANI PHARMACEUTICALS Reports Q4 EPS $1.00, vs. Street Est of $0.86	Feb. 29	MT
ANI Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
ANI Pharmaceuticals Launches Pentoxifylline Extended-Release Tablets	Jan. 23	MT
ANI Pharmaceuticals Announces the Launch of Pentoxifylline Extended-Release Tablets, USP	Jan. 23	CI
ANI Pharmaceuticals Receives US FDA Approval for Indomethacin Oral Suspension	Jan. 16	MT
ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Indomethacin Oral Suspension, USP	Jan. 16	CI
Lupin Gets US FDA Nod for Hypertension Treatment Drug	Jan. 14	MT
ANI Pharmaceuticals Shares Fall Despite Higher Q3 Results, Raised 2023 Guidance	Nov. 08	MT
ANI Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
(ANIP) ANI PHARMACEUTICALS Sees Fiscal Year 2023 EPS Range $4.29 - $4.57	Nov. 08	MT
Earnings Flash (ANIP) ANI PHARMACEUTICALS Reports Q3 Revenue $131.8M	Nov. 08	MT
Earnings Flash (ANIP) ANI PHARMACEUTICALS Posts Q3 EPS $1.27	Nov. 08	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights ANI Pharmaceuticals, Inc.

Equities

ANIP

US00182C1036

Highlights

Filters